BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+29.8%
5Y CAGR+38.7%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
+29.8%/yr
vs +52.4%/yr prior
5Y CAGR
+38.7%/yr
Recent deceleration
Acceleration
-22.6pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
5.1x
Strong expansion
Streak
9 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $348.65M | +31.0% |
| 2024 | $266.13M | +24.4% |
| 2023 | $213.89M | +34.2% |
| 2022 | $159.37M | +34.1% |
| 2021 | $118.82M | +74.9% |
| 2020 | $67.93M | +83.0% |
| 2019 | $37.12M | +25.8% |
| 2018 | $29.51M | +111.8% |
| 2017 | $13.93M | +23.8% |
| 2016 | $11.25M | - |